玻璃体腔注药联合视网膜激光治疗视网膜静脉阻塞并发黄斑水肿的临床观察

Clinical observation on the treatment of retinal vein occlusion by vitreous injection combined with retinal laser

目的:比较玻璃体腔注射康柏西普后结合激光治疗视网膜静脉阻塞并发黄斑水肿效果。方法:选取我院2019年5月至2020年10月收治的60例(60眼)视网膜静脉阻塞继发黄斑水肿的患者,随机分为观察组与对照组各30例(30眼),观察组行康柏西普联合激光治疗,对照组行视网膜激光治疗,比较两组治疗效果。结果:两组患者治疗前黄斑中心凹厚度(CMT)指标对比无差异(P>0.05),治疗后观察组患者CMT指标显著低于对照组(P<0.05)。术后1个月观察组视力提高率为93.33%,有2例患者出现视力下降;对照组视力提高率为73.33%,有8例患者出现视力下降;两组对比差异有统计学意义(P<0.05)。观察组术后黄斑水肿再复发率为13.33%,显著低于对照组的36.67%(P<0.05)。结论:玻璃体腔注射康柏西普联合激光治疗视网膜静脉阻塞继发黄斑水肿疗效显著,可提升视力水平,降低黄斑中心凹厚度,减少黄斑水肿再发生率,值得临床推广应用。

Objective:To compare the clinical effects of intravitreal injection of Conbercept combined with retinal laser and retinal laser alone in the treatment of retinal vein occlusion complicated with macular edema.Methods:We selected 60 patients(60 eyes)with retinal vein occlusion and macular edema who were hospitalized in our hospital from May 2019 to October 2020.They were divided into observation group(group A)and control group(group B)with 30 cases each(30 eyes)randomly.The observation group were treated with Conbercept combined with laser treatment,and the control group were treated with retinal laser treatment.We compared the treatment effects of the two groups.Results:There was no significant difference in the levels of CMT and BCVA between the two groups before treatment(P>0.05).The levels of CMT and BCVA in the observation group after treatment were significantly improved compared with the control group,and the difference was statistically significant(P<0.05).The recurrence rate of macular edema after treatment in the observation group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Conbercept combined with laser treatment of retinal vein occlusion complicated macular edema has a significant effect,which can effectively improve the visual acuity of patients,reduce the thickness of the fovea,and reduce the recurrence rate of macular edema,which is worthy of clinical application.